Plain-English translation of NCT07881120 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help improve skin symptoms in people with cutaneous lupus erythematosus (CLE) whose disease hasn't responded well to standard treatments. works by blocking certain inflammatory pathways in the immune system. The study will compare this medication to a placebo (a dummy pill with no active ingredient) over 24 weeks, then offer the active medication to everyone for an additional 28 weeks.
Many people with cutaneous lupus don't respond well to or can't tolerate the standard antimalarial medications currently available. This trial exists to see if this medication offers a new option for people whose skin lupus remains active despite existing treatments.
You likely qualify if…
You likely don't qualify if…
You will take one capsule by mouth every day for a total of 52 weeks (one year). For the first 24 weeks, you'll randomly receive either the new medication or a placebo, and neither you nor the study team will know which one. After 24 weeks, everyone receives the active medication for an additional 28 weeks. Throughout the study, you'll visit the clinic regularly so doctors can examine your skin and monitor your health through blood tests and other assessments.
AI-generated summary from trial data · Oct 29, 2026 · Not medical advice
United States